CN115605219A - 一种治疗病毒性肺炎的方法和药物 - Google Patents

一种治疗病毒性肺炎的方法和药物 Download PDF

Info

Publication number
CN115605219A
CN115605219A CN202180012683.0A CN202180012683A CN115605219A CN 115605219 A CN115605219 A CN 115605219A CN 202180012683 A CN202180012683 A CN 202180012683A CN 115605219 A CN115605219 A CN 115605219A
Authority
CN
China
Prior art keywords
plasminogen
pneumonia
plasmin
sequence
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180012683.0A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN115605219A publication Critical patent/CN115605219A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种治疗病毒性肺炎的方法，包括给药受试者治疗有效量的纤维蛋白溶酶原激活途径组分。还涉及用于治疗病毒性肺炎的包含纤维蛋白溶酶原激活途径组分的药物、药物组合物、制品、试剂盒。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180012683.0A 2020-02-11 2021-02-08 一种治疗病毒性肺炎的方法和药物 Pending CN115605219A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010086980 2020-02-11
CN2020100869807 2020-02-11
PCT/CN2021/076035 WO2021160092A1 (zh) 2020-02-11 2021-02-08 一种治疗病毒性肺炎的方法和药物

Publications (1)

Publication Number Publication Date
CN115605219A true CN115605219A (zh) 2023-01-13

Family

ID=77292057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180012683.0A Pending CN115605219A (zh) 2020-02-11 2021-02-08 一种治疗病毒性肺炎的方法和药物

Country Status (8)

Country Link
US (1) US20230081922A1 (zh)
EP (1) EP4094776A4 (zh)
JP (1) JP2023521530A (zh)
KR (1) KR20220137946A (zh)
CN (1) CN115605219A (zh)
CA (1) CA3167593A1 (zh)
TW (1) TWI788779B (zh)
WO (1) WO2021160092A1 (zh)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU3765897A (en) * 1996-08-14 1998-03-06 Jurgen Brodersen Gram Use of a plasminogen activator for the treatment of pulmonary disorders
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
CN101563100B (zh) * 2006-08-28 2013-08-07 李季男 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
US20080214682A1 (en) * 2006-12-22 2008-09-04 Washington University In St. Louis Methods of treating pneumonic plague
US8697840B2 (en) * 2008-03-05 2014-04-15 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
US20100254979A1 (en) * 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
EA033403B1 (ru) * 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
BR112017018209A2 (pt) * 2015-02-27 2018-04-17 Board Of Regents, The University Of Texas System produtos terapêuticos de polipeptídeo e usos dos mesmos
US11090372B2 (en) * 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
US11219669B2 (en) * 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis

Also Published As

Publication number Publication date
WO2021160092A1 (zh) 2021-08-19
EP4094776A1 (en) 2022-11-30
JP2023521530A (ja) 2023-05-25
KR20220137946A (ko) 2022-10-12
US20230081922A1 (en) 2023-03-16
TW202130361A (zh) 2021-08-16
TWI788779B (zh) 2023-01-01
CA3167593A1 (en) 2021-08-19
EP4094776A4 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
CA3008694C (en) Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
TWI725092B (zh) 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
CA3008475C (en) Method for preventing and treating hepatic tissue injury and related disorders thereof
TWI734798B (zh) 一種預防和治療肺纖維化的方法
CA3047181A1 (en) Method and drug for preventing and treating obesity
CN116490200A (zh) 一种提高ngf水平的方法和药物
CA3008466C (en) Method for preventing or treating radiation and chemical damage
EP4091621A1 (en) Method for treatment of nerve injury and related disease
TWI788779B (zh) 一種治療病毒性肺炎的方法和藥物
TWI811675B (zh) 一種治療脊髓性肌萎縮症的方法和藥物
WO2021180068A1 (zh) 一种治疗2019新型冠状病毒引发疾病的方法和药物
CN111905103A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
TWI853151B (zh) 一種預防和治療血壓異常病症的方法和藥物
WO2021170099A1 (zh) 一种预防和治疗血压异常病症的方法和药物
CN113795274A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
TW202228766A (zh) 一種治療神經損傷及其相關病症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination